Severe acute respiratory syndrome coronavirus 2 spike protein S1 receptor-binding domain (SARS-CoV-2 S1 RBD) (SARS-CoV-2 S1 RBD)

The SARS-CoV-2 spike protein S1 receptor-binding domain (RBD) is a critical structural component of the virus that facilitates entry into human host cells. It functions by specifically recognizing and binding to the Angiotensin-Converting Enzyme 2 (ACE2) receptor located on the surface of various human tissues, particularly in the respiratory tract [1, 2]. This high-affinity interaction at the RBD-ACE2 interface is the initial and essential step for viral infection, making it the primary target for the development of neutralizing antibodies and vaccines [4]. Therapeutic monoclonal antibodies are designed to bind to the RBD, sterically blocking its access to the ACE2 receptor and preventing the virus from docking and entering the cell [3]. However, the RBD is a hotspot for mutations, leading to the emergence of variants that can evade existing immune responses and therapeutic agents, presenting a significant challenge for long-term clinical management [1, 3]. Consequently, monitoring the structural evolution of this interface is vital for maintaining the efficacy of COVID-19 countermeasures.

Other names

SARS-CoV-2 S1-RBDSpike RBDReceptor-binding domain of the S1 subunitSARS-CoV-2 S-RBD

Neutralization of viral entry by competitively binding to the S1 receptor-binding domain, thereby blocking its interaction with the host cell Angiotensin-Converting Enzyme 2 (ACE2) receptor [2, 3].